Navigation Links
SynergEyes, Inc. Raises $13.3 Million in 'Series C' Financing
Date:2/6/2009

CARLSBAD, Calif., Feb. 6 /PRNewswire/ -- SynergEyes, Inc., the high Dk hybrid contact lens manufacturer, announced today the closing of $13.3 million in Series C financing to fund the development and clinical trials for next-generation hybrid contact lens products and to expand sales and marketing efforts globally.

De Novo Ventures of Palo Alto, CA, led this round as well as SynergEyes' Series B round. Bio-Star Private Equity Fund joined Series A and B investors: Alloy Ventures, Delphi Ventures, InnoCal Venture Capital and Windward Ventures as a new investor.

Based in Carlsbad, CA, SynergEyes has developed a new type of contact lens that combines two materials -- a rigid gas permeable center and a soft, hydrophilic outer skirt. The result is a durable "hybrid" lens for patients seeking crisp, clear vision and the all-day comfort of a soft lens.

"SynergEyes sincerely appreciates the continued commitment of our venture capital partners and their support of the vision and mission of SynergEyes. Their investment will ensure that the millions of patients in need of our technology will have access to the many features and benefits only a hybrid contact lens can offer," said Paul Kammann, CFO of SynergEyes, Inc.

"SynergEyes hybrid contact lenses represent a significant advancement in the contact lens industry and give eye care professionals a one-of-a-kind tool to satisfy one of the largest growing patient categories in the world," said Jim Ham, CEO for SynergEyes, Inc. "SynergEyes has demonstrated substantial revenue growth since market introduction in 2006. Our next-generation products will re-define state-of-the-art in the vision correction industry."

Jay Watkins, managing director of De Novo Ventures, expressed his firm's continued support for SynergEyes: "SynergEyes continues to demonstrate significant progress towards becoming a world-class vision care company. Hybrid co
'/>"/>

SOURCE SynergEyes, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Globus Medical Raises $110 Million in Series E Financing Round
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
4. Romark Laboratories Raises $18 Million in Institutional Financing
5. Light Sciences Oncology Raises $40.1 Million in Series C Financing
6. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
7. ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
8. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
9. Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
10. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
11. Atritech Announces Completion of a $22 Million Equity Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
(Date:1/15/2014)...  In an unprecedented effort to curb the spread of "superbugs" such ... vehicles, an advanced and portable UV germicidal lamp manufactured by MRSA-UV ... In order to prevent EMS paramedics and transport ... West Palm Beach Fire Rescue is the first in ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Frontage Laboratories, Inc., a ... US and China, and Spaulding Clinical Research, LLC, a ... Medical Device Manufacturer have entered into a strategic partnership ... footprint by combining Frontage,s presence in China and its ...
... SPRING, Md., Sept. 12, 2011 Today, the U.S. ... office responsible for reviewing all drug and biologic applications ... Research,s (CDER) Office of Oncology Drug Products has been ... Products (OHOP). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) ...
Cached Medicine Technology:Spaulding Clinical Announces New Strategic Partnership With Frontage Laboratories, Inc. 2Spaulding Clinical Announces New Strategic Partnership With Frontage Laboratories, Inc. 3FDA Announces Changes in Drug Center's Oncology Office 2FDA Announces Changes in Drug Center's Oncology Office 3
(Date:4/17/2014)... Men who show signs of chronic inflammation in non-cancerous ... actually having prostate cancer than those with no inflammation, ... researchers from the Johns Hopkins Kimmel Cancer Center. , ... stronger for men with so-called high-grade prostate cancer ... indicating the presence of the most aggressive and ...
(Date:4/17/2014)... the April issue of Experimental Biology and ... Drs. Rex Gaskins and Paul Kenis in the ... of the University of Illinois Urbana-Champaign describe their ... reactions underlie a variety of cell functions including ... these crucial roles in regulating normal cellular behavior, ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
(Date:4/17/2014)... potential to ward off depression among retirees, particularly among ... in The Journals of Gerontology, Series B: ... article " Internet Use and Depression Among Retired Older ... the authors report that Internet use reduced the probability ... study sample. , Late-life depression affects between 5 ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Internet use may cut retirees' depression 2
... been found to reduce the risk of cellular ... top of standard immunosuppression. ,The drug, a ... receptor, thereby inhibiting T-cell proliferation. ,Patients who ... daclizumab or a placebo. ,The primary endpoint ...
... severe depression 'Transcranial Magnetic Stimulation' (TMS) maybe the ... the more aggressive electro-shock therapy., ,Electro-Shock Therapy or ... resort to treat severe depression for many decades. However, ... after therapy and requires general anesthesia. In ECT the ...
... people in the United States, Europe and Japan and many ... drinking calcium water may help in reducing osteoporosis., ,Calcium ... the people do not consume enough of this nutrient. ... osteoporosis but for many teenagers, and those in their twenties ...
... 598 068 nuclear industry workers from 15 countries.// The ... after administrating low doses of radiation. ,This study ... risk among radiation workers in the nuclear industry to ... dose exposure of radiation. ,The study recruits were ...
... time may be putting their health more at risk than ... that feeing angry for a very long time may cause ... pick up habits like smoking and drinking, or inducing stress ... of the literature that had tried to relate to various ...
... suffering from congenital central hypoventilation syndrome (CCHS) may suffer ... ,Congenital Central Hypoventilation Syndrome is the absence ... time. Children suffering from CCHS may not breathe regularly ... may be able to breathe during wakeful hours but ...
Cached Medicine News:Health News:Strong Magnetic Stimulation Can Help Treating Severe Depression 2Health News:Cancer risk among nuclear industry workers 2
Adhesive tape sheets for sealing multiwell plates and blocks;...
Microwell Plate Accessories...
DMSO-resistant microplate sealing film...
Amplification Tape 96 featuring 3M adhesive technology. Good optical quality. Minimal autofluorescence. Certified RNase and DNase free....
Medicine Products: